LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced an arrangement with Eli Lilly and Company (Lilly) that enables LifeMD's affiliated pharmacy to directly dispense and ship Lilly's self-pay GLP-1 medicines, including Zepbound® (tirzepatide) and Foundayo® (orforglipron), to eligible patients across the United States.

Under the arrangement, eligible patients prescribed a Lilly medication by a LifeMD-affiliated healthcare provider following an independent clinical evaluation can purchase that medication at Lilly's established self-pay price directly through LifeMD. Prescriptions will be fulfilled and shipped by LifeMD's licensed mail-order pharmacy, creating a seamless patient experience from consultation and prescribing to fulfillment and home delivery. The program includes both Zepbound® and Foundayo®. Lilly and LifeMD will continue to explore opportunities to expand access to additional medicines in the future. 

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.